 |
市場調查報告書
商品編碼
1629594
白細胞介素抑制劑市場：按類型、按給藥途徑、按應用、按分銷管道、按地區Interleukin Inhibitors Market, By Type, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
2024 年全球白細胞介素抑制劑市場規模估計為 326 億美元，預計 2031 年將達到 748.1 億美元，2024 年至 2031 年的複合年成長率為 12.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2023 | 2024 年的市場規模 | 326億美元 |
| 效能資料 | 2019 年至 2023 年 | 預測期 | 2024 年至 2031 年 |
| 預測期間 2024 年至 2031 年複合年成長率： | 12.60％ | 2031 年價值預測 | 748.1億美元 |
白細胞介素抑制劑是阻斷或減弱白細胞介素細胞激素活性的生技藥品，白細胞介素細胞因子在引發發炎中發揮重要作用。這些蛋白質作為重要的訊號分子，引導白血球遷移到受傷或感染的部位。然而，過度或長期的發炎可能會導致問題。白細胞介素抑制劑針對特定的白細胞介素，有助於控制由不適當或過度的免疫反應引起的病症。它針對與自體免疫疾病相關的關鍵白細胞介素，包括 IL-17、IL-23 和 IL-1B。隨著新型生技藥品被核准用於治療各種發炎和免疫介導疾病，全球白細胞介素抑制劑市場正在穩步成長。
市場動態：
全球白細胞介素抑制劑市場受到全球免疫相關疾病的增加和醫療保健支出的增加所推動。根據世界衛生組織估計，到2024年11月，全球約有2-3%的人口將患有自體免疫疾病，其中許多病例未診斷或治療。新型白細胞介素抑制劑核准用於治療乾乾癬性關節炎、僵直性脊椎炎、潰瘍性大腸炎等尚未滿足醫療需求的疾病，也推動了市場的成長。然而，生技藥品的高成本對於價格敏感的新興市場的市場擴張構成了重大挑戰。此外，重磅藥物的專利懸崖進一步加劇了競爭。也就是說，正在進行的研究和開發具有更安全性和新治療適應症的白細胞介素介素抑制劑為市場上的公司提供了有吸引力的機會。
本研究的主要特點
本報告對全球白細胞介素抑制劑市場進行了詳細分析，並以 2023 年為基準年，展示了預測期（2024-2031 年）的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
全球白細胞介素抑制劑市場的主要企業根據公司亮點、產品系列、關鍵亮點、性能和策略等參數進行分析。
研究涉及的主要企業包括 AbbVie Inc.、強生公司、安進公司、諾華公司、賽諾菲公司、葛蘭素史克公司、禮來公司、再生元製藥公司、默克公司、武田製藥有限公司、Biogen Inc.、UCB SA、安斯泰來製藥公司、拜耳公司和山德士國際有限公司。
本報告的見解將幫助負責人和企業經營團隊就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員將透過分析全球白細胞介素抑制劑市場所使用的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要進展
- 監管情景
- 產品發布/核准
- PEST分析
- PORTER 分析
- 併購情景
- 產業趨勢
4. 全球白細胞介素抑制劑市場，依類型，2019-2031 年
- IL-1 抑制劑
- IL-5 抑制劑
- IL-6 抑制劑
- IL-17 抑制劑
- IL-23 抑制劑
- 其他類型
5. 全球白細胞介素抑制劑市場，依給藥途徑，2019-2031 年
- 口服
- 皮下（SC）
- 靜脈注射 (IV)
- 其他
6. 全球白細胞介素抑制劑市場，依應用，2019-2031 年
- 類風濕性關節炎
- 乾癬性關節炎
- 乾癬
- 發炎性腸道疾病(IBD)
- 氣喘
- 多發性硬化症
- 潰瘍性大腸炎
- 克隆氏症
- 其他用途
7. 全球白細胞介素抑制劑市場，按分銷管道，2019-2031 年
- 醫院藥房
- 零售藥局
- 網路藥局
8. 全球白細胞介素抑制劑市場，按地區，2019-2031 年
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第9章 競爭格局
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi SA
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB SA
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
第 10 章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第 11 章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 32.60 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 12.60% | 2031 Value Projection: | US$ 74.81 Bn |
Interleukin inhibitors are biologics that block or dampen the activity of interleukin cytokines that play important roles in triggering inflammation. These proteins act as signaling molecules that are critical in directing the movement of white blood cells to sites of injury or infection. However, excess or prolonged inflammation can cause issues. Interleukin inhibitors help control conditions driven by inappropriate or excessive immune responses by targeting specific interleukins. Some key interleukin targets include IL-17, IL-23, and IL-1B that are implicated in autoimmune diseases. The global interleukin inhibitors market has been growing steadily as new biologics gain regulatory approvals for treating various inflammatory and immune-mediated disorders.
Market Dynamics:
The global interleukin inhibitors market is driven by the increasing prevalence of immune-mediated conditions worldwide coupled with rising healthcare expenditures. In November 2024, according to the WHO estimates, around 2-3% of the global population suffers from autoimmune diseases with many cases remaining undiagnosed or untreated. Approvals of novel interleukin inhibitors for treating diseases with high unmet needs such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis are also boosting the market growth. However, high costs of biologics pose a major challenge for market expansion in price-sensitive developing regions. Moreover, patent cliffs of blockbuster drugs further intensify competition. Nevertheless, ongoing R&D for developing interleukin inhibitors with improved safety profiles and new therapeutic indications provide attractive opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global interleukin inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global interleukin inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global interleukin inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interleukin inhibitors market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2031)
- IL-1 inhibitors
- IL-5 inhibitors
- IL-6 inhibitors
- IL-17 inhibitors
- IL-23 inhibitors
- Other types
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
- Others
- By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Asthma
- Multiple Sclerosis
- Ulcerative colitis
- Crohn's disease
- Other applications
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Interleukin Inhibitors Market, By Type
- Global Interleukin Inhibitors Market, By Route of Administration
- Global Interleukin Inhibitors Market, By Application
- Global Interleukin Inhibitors Market, By Distribution Channel
- Global Interleukin Inhibitors Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Interleukin Inhibitors Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- IL-1 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-5 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-6 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-17 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-23 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Other types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Interleukin Inhibitors Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Interleukin Inhibitors Market, By Application, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Rheumatoid arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Psoriatic arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Inflammatory bowel disease (IBD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Ulcerative colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Other applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Interleukin Inhibitors Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Interleukin Inhibitors Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
